LYEL
Lyell Immunopharma, Inc.Company Information
- Company Name
- Lyell Immunopharma, Inc.
- CIK
- CIK0001806952
- Category
- Non-accelerated filer<br>Smaller reporting company
- Ticker: Exchange
- LYEL: Nasdaq
- Fiscal Year End
- December 31
- Owner Organization
- 03 Life Sciences
- SIC
- 2834
- SIC Description
- Pharmaceutical Preparations
- Ticker
- LYEL
SEC filing data through
Insider Sentiment
- Last purchase
- 2026-03-06
- Last sale
- 2026-09-10
- Shares purchased (TTM)
- 976,180
- Shares sold (TTM)
- 29,717
Institutional Sentiment
- As of
- 2026-06-30
- Institutional shares owned
- 11,936,893
- Shares outstanding
- 23,364,000
- Ownership
- 51.09%
Earnings Market Reaction
- Filing date
- 2026-08-06
- Price on filing date
- —
- 1-month reaction
- 2.25%
- 3-month reaction
- …
Balance Sheet
Values in millions ($)| Line item | 2026-06-30 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 | 2025-03-31 | 2024-12-31 | 2024-09-30 | 2024-06-30 | 2024-03-31 | 2023-12-31 | 2023-09-30 | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Subscriber-only column | Trend |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Assets Current | ||||||||||||||||||
| Cash And Cash Equivalents At Carrying Value | 73 | 91 | 60 | 124 | 99 | 120 | 106 | 100 | 133 | 126 | 146 | 286 | ||||||
| Marketable Securities Current | 131 | 163 | 187 | 196 | 178 | 181 | 265 | 340 | 358 | 401 | 401 | 289 | ||||||
| Prepaid Expense And Other Assets Current | 9 | 13 | 14 | 9 | 5 | 8 | 9 | 9 | 9 | 8 | 8 | 11 | ||||||
| Assets Current | 214 | 267 | 261 | 328 | 282 | 309 | 380 | 450 | 500 | 534 | 555 | 587 | ||||||
| Restricted Cash Noncurrent | 2 | 2 | 2 | 2 | 2 | 2 | 2 | 0 | 0 | 0 | 0 | 0 | ||||||
| Marketable Securities Noncurrent | 24 | 7 | 0 | 0 | 20 | 29 | 13 | 20 | 0 | 0 | 17 | 23 | ||||||
| Other Investments | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 19 | 32 | 32 | ||||||
| Property Plant And Equipment Net | 31 | 33 | 35 | 37 | 39 | 44 | 48 | 88 | 93 | 98 | 103 | 108 | ||||||
| Operating Lease Right Of Use Asset | 17 | 18 | 19 | 20 | 21 | 24 | 25 | 37 | 38 | 39 | 40 | 41 | ||||||
| Other Assets Noncurrent | 6 | 5 | 5 | 3 | 3 | 3 | 5 | 5 | 4 | 4 | 4 | 4 | ||||||
| Assets | 311 | 351 | 340 | 408 | 385 | 430 | 491 | 619 | 654 | 694 | 750 | 795 | ||||||
Liabilities Current | ||||||||||||||||||
| Accounts Payable Current | 4 | 5 | 3 | 3 | 3 | 4 | 5 | 4 | 4 | 5 | 5 | 4 | ||||||
| Accrued Liabilities And Other Liabilities | 36 | 31 | 47 | 29 | 28 | 31 | 41 | 29 | 26 | 25 | 28 | 30 | ||||||
| Asset Acquisition Contingent Consideration Liability Current | - | - | 0 | 0 | 6 | 6 | 8 | - | - | - | 0 | - | ||||||
| Liabilities Current | 40 | 37 | 49 | 32 | 37 | 41 | 54 | 34 | 31 | 32 | 35 | 35 | ||||||
| Operating Lease Liability Noncurrent | 37 | 39 | 42 | 44 | 47 | 49 | 51 | 51 | 53 | 55 | 57 | 59 | ||||||
| Other Liabilities Noncurrent | 1 | 1 | 1 | 3 | 3 | 3 | 3 | 4 | 3 | 4 | 4 | 4 | ||||||
| Liabilities | 77 | 77 | 92 | 79 | 87 | 93 | 108 | 89 | 88 | 91 | 95 | 97 | ||||||
Stockholders Equity Including Portion Attributable To Noncontrolling Interest | ||||||||||||||||||
| Preferred Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Value | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Additional Paid In Capital | 1,922 | 1,917 | 1,868 | 1,808 | 1,739 | 1,734 | 1,728 | 1,683 | 1,675 | 1,666 | 1,657 | 1,648 | ||||||
| Accumulated Other Comprehensive Income Loss Net Of Tax | -0 | -0 | 0 | 0 | 0 | 0 | 0 | 1 | -0 | -0 | -0 | -1 | ||||||
| Retained Earnings Accumulated Deficit | -1,688 | -1,644 | -1,620 | -1,479 | -1,440 | -1,397 | -1,345 | -1,153 | -1,109 | -1,063 | -1,002 | -949 | ||||||
| Stockholders Equity | 234 | 274 | 248 | 329 | 299 | 337 | 383 | 531 | 567 | 603 | 655 | 698 | ||||||
| Liabilities And Stockholders Equity | 311 | 351 | 340 | 408 | 385 | 430 | 491 | 619 | 654 | 694 | 750 | 795 | ||||||
| Preferred Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Preferred Stock Shares Authorized | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | 10 | ||||||
| Preferred Stock Shares Issued | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Preferred Stock Shares Outstanding | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | ||||||
| Common Stock Par Or Stated Value Per Share | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||||
| Common Stock Shares Authorized | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | 500 | ||||||
| Common Stock Shares Issued | 23 | 23 | 21 | 19 | 15 | 15 | 15 | 13 | 13 | 13 | 13 | 13 | ||||||
| Shares Outstanding | 23 | 23 | 21 | 19 | 15 | 15 | 15 | 13 | 13 | 13 | 13 | 13 | ||||||
| Stockholders Equity Note Stock Split Conversion Ratio1 | - | - | - | - | 0 | - | - | - | - | - | - | - | ||||||
Select a line item above to chart it.
Recent filings
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
- 10-QFiled
- 10-QFiled
- 10-KFiled
- 10-QFiled
Financial statements beyond 3 years are for subscribers only.
Unlock 17+ years of income statements, balance sheets, and cash flow statements
Start 7-day free trialLyell Immunopharma, Inc. (LYEL) — SEC Financial Statements & Analysis
Lyell Immunopharma, Inc. (LYEL) is a pharmaceutical preparations company, incorporated in DE. Lyell Immunopharma, Inc. trades on Nasdaq as: LYEL. Lyell Immunopharma, Inc. (LYEL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06. Based on that filing, Lyell Immunopharma, Inc. carries a market cap of $328.26M, a P/E ratio of -1.32x, a P/B ratio of 1.40x, a P/S ratio of 12157.93x, an enterprise value of $253.69M, and an EV/EBITDA multiple of -1.03x. On profitability, it posts an operating margin of -949981.48%, a net margin of -920285.19%, a Return on Equity (ROE) of -93.28%, a Return on Assets (ROA) of -71.34%, and a Return on Invested Capital (ROIC) of -143.38%. Per share, it reports EPS of $-10.64, diluted EPS of $-10.64, free cash flow per share of $-5.73, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -55.00% year-over-year, net income growth of -25.02% year-over-year, and EPS growth of -52.53% year-over-year. On the balance sheet, it maintains a current ratio of 5.36x, a quick ratio of 5.12x, working capital of $173.67M, a debt-to-equity ratio of 0.33x, a debt ratio of 0.25, an interest coverage ratio of -24.85x, free cash flow of $-133.97M (TTM), and net debt of $-74.57M. Figures sourced from SEC EDGAR.
- Market Cap
- $328.26M
- P/E TTM
- -1.32x
- EPS TTM
- $-10.64
- P/B TTM
- 1.40x
- ROE TTM
- -93.28%
- ROA TTM
- -71.34%
- Debt To Equity
- 0.33x
- Free Cash Flow TTM
- $-133.97M
- Net Revenue TTM Growth 1Y
- -55.00%
Data as of 2026-06-30 · Source: SEC EDGAR
Frequently Asked Questions
What industry is Lyell Immunopharma, Inc. in?
Lyell Immunopharma, Inc. (LYEL) operates in the Pharmaceutical Preparations industry.
What exchange does LYEL trade on?
Lyell Immunopharma, Inc. (LYEL) trades on the Nasdaq.
Where is Lyell Immunopharma, Inc. incorporated?
Lyell Immunopharma, Inc. is incorporated in DE.
When was Lyell Immunopharma, Inc. (LYEL)'s most recent SEC filing?
Lyell Immunopharma, Inc. (LYEL)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-06.
What is LYEL's market cap?
Lyell Immunopharma, Inc. (LYEL) has a market capitalization of $328.26M as of 2026-06-30.
What is LYEL's EPS (earnings per share)?
Lyell Immunopharma, Inc. (LYEL)'s trailing twelve month EPS is $-10.64 as of 2026-06-30.
What is LYEL's ROE (return on equity)?
Lyell Immunopharma, Inc. (LYEL)'s trailing twelve month Return on Equity (ROE) is -93.28% as of 2026-06-30.
What is LYEL's ROA (return on assets)?
Lyell Immunopharma, Inc. (LYEL)'s trailing twelve month Return on Assets (ROA) is -71.34% as of 2026-06-30.
What is LYEL's ROIC (return on invested capital)?
Lyell Immunopharma, Inc. (LYEL)'s trailing twelve month Return on Invested Capital (ROIC) is -143.38% as of 2026-06-30.
What is LYEL's EV/EBITDA?
Lyell Immunopharma, Inc. (LYEL)'s trailing twelve month EV/EBITDA is -1.03x as of 2026-06-30.